{"id":"tacrolimus-entecavir","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Lactic acidosis (entecavir-related)"}]},"_chembl":{"chemblId":"CHEMBL713","moleculeType":"Small molecule","molecularWeight":"277.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus is a calcineurin inhibitor that prevents T-cell activation and proliferation, commonly used in transplant recipients to prevent organ rejection. Entecavir is a nucleoside reverse transcriptase inhibitor that blocks hepatitis B virus replication. This combination addresses both immunosuppression needs and chronic hepatitis B infection in transplant patients.","oneSentence":"This combination uses tacrolimus to suppress immune rejection and entecavir to inhibit hepatitis B virus reverse transcriptase.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:10:43.435Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant recipients with chronic hepatitis B infection"}]},"trialDetails":[{"nctId":"NCT03062813","phase":"PHASE4","title":"Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN)","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2017-02-01","conditions":"Hepatitis B Virus Associated Nephrotic Syndrome","enrollment":112}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FK506,Prograf, baraclude"],"phase":"marketed","status":"active","brandName":"Tacrolimus &entecavir","genericName":"Tacrolimus &entecavir","companyName":"Guangdong Provincial People's Hospital","companyId":"guangdong-provincial-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses tacrolimus to suppress immune rejection and entecavir to inhibit hepatitis B virus reverse transcriptase. Used for Organ transplant recipients with chronic hepatitis B infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}